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Key points
 Theplacenta removeswaste products, drugs and environmental toxins from the fetal circulation
and two of the transport proteins responsible for this are OAT4 and OATP2B1 localised to the
basal membrane of placental syncytiotrophoblast.
 We provide evidence that OAT4 and OATP2B1 mediate glutamate efflux when expressed
in Xenopus oocytes and that in the perfused placenta, bromosulphothalein (an OAT4 and
OATP2B1 substrate) stimulates glutamate efflux.
 Furthermore the efflux of glutamate can only be seen in the presence of aspartate, which will
block glutamate reuptake by the placenta, consistent with cycling of glutamate across the basal
membrane.
 We propose that glutamate efflux down its transmembrane gradient drives placental uptake
via OAT4 and OATP2B1 from the fetal circulation and that reuptake of glutamate maintains
this driving gradient.
Abstract The organic anion transporter OAT4 (SLC22A11) and organic anion transporting
polypeptide OATP2B1 (SLCO2B1) are expressed in the basal membrane of the placental
syncytiotrophoblast. These transporters mediate exchange whereby uptake of one organic anion
is coupled to efflux of a counter-ion. In placenta, these exchangers mediate placental uptake of
substrates for oestrogen synthesis as well as clearing waste products and xenobiotics from the
fetal circulation. However, the identity of the counter-ion driving this transport in the placenta,
and in other tissues, is unclear. While glutamate is not a known OAT4 or OATP2B1 substrate,
we propose that its high intracellular concentration has the potential to drive accumulation of
substrates from the fetal circulation. In the isolated perfused placenta, glutamate exchange was
observed between the placenta and the fetal circulation. This exchange could not be explained by
known glutamate exchangers. However, glutamate efflux was trans-stimulated by an OAT4 and
OATP2B1 substrate (bromosulphothalein). Exchange of glutamate for bromosulphothalein was
only observed when glutamate reuptake was inhibited (by addition of aspartate). To determine
if OAT4 and/or OATP2B1 mediate glutamate exchange, uptake and efflux of glutamate were
investigated in Xenopus laevis oocytes. Our data demonstrate that in Xenopus oocytes expressing
either OAT4 orOATP2B1 efflux of intracellular [14C]glutamate could be stimulated by conditions
including extracellular glutamate (OAT4), estrone-sulphate and bromosulphothalein (bothOAT4
and OATP2B1) or pravastatin (OATP2B1). Cycling of glutamate across the placenta involving
efflux via OAT4 and OATP2B1 and subsequent reuptake will drive placental uptake of organic
anions from the fetal circulation.
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Introduction
Many therapeutic drugs and environmental chemicals are
potentially teratogenic in pregnancy. To protect the fetus,
the placenta expresses transporters and enzymes that pre-
vent transfer of xenobiotics to the fetus or remove them
fromthe fetal circulation (Prouillac&Lecoeur, 2010; Staud
& Ceckova, 2015). However, as the tragic example of
thalidomide demonstrates, the placenta is by no means
a perfect barrier.
The organic anion transporters (OATs) and the organic
anion transporting polypeptides (OATPs) are two trans-
porter families which mediate the transport of drugs
and endogenous substrates in cells throughout the body
(Hagenbuch & Stieger, 2013; Koepsell, 2013). In the
human placenta, OAT4 (human gene symbol SLC22A11)
and OATP2B1 (SLCO2B1) are localised to the fetal-facing
basal membrane (BM) and so will mediate transfer
between the placenta and the fetal circulation (Ugele et al.
2003). The OATs and OATPs are widely expressed across
species but OAT4 is found in humans and monkey but
not in rodents (Koepsell, 2013). The OATs and OATPs
are exchangers, mediating uptake of one molecule in
exchange for efflux of another. In theory, this means that
OAT4 and OATP2B1 could transport xenobiotics both to
and from the fetal circulation. However, whether they
transport xenobiotics in both directions or in only one
direction will depend on the interaction with other sub-
strates. For instance, the exchanger xCT (SLC7A11) can
transport glutamate and cystine in either direction but
in practice will primarily mediate cystine uptake. This
is because the high intracellular glutamate concentration
will competitively inhibit cystine efflux via xCT while
driving uptake of cystine by secondary active transport
(Sato et al. 1999).
Whether the OATs and OATPs on the BM of the
placental syncytiotrophoblast transfer xenobiotics to the
fetus, from the fetus or in both directions will depend
on the balance of intra- and extracellular concentration
of substrates. Intracellular glutamate concentrations in
placenta, liver and muscle are reported to be greater than
4 mmol l−1 compared to 0.05 mmol l−1 in plasma, a
transmembrane gradient of 80:1 (Philipps et al. 1978;
Vinnars et al. 1980; Barle et al. 1996; Stanley, 2009).
If OAT4 and OATP2B1 were coupled to an outwardly
directed gradient such as glutamate this would drive
uptake of xenobiotics out of the fetal circulation thus
helping to protect the fetus. Furthermore, this would
drive placental uptake of endogenous OAT substrates,
including dehydroepiandrosterone-3-sulfate (DHEAS).
The placenta cannot synthesise DHEAS and must take
it up from the mother and the fetus in order to synthesise
the oestrogen required to maintain pregnancy (Siiteri,
2005; Prouillac & Lecoeur, 2010). Coupling of OAT4 and
OATP2B1 to an outwardly directed glutamate gradient
would drive uptake of DHEAS and many xenobiotics
from the fetal circulation and into the placenta. For this
reason, it would make sense that these transporters were
coupled to a counter-ion; however, no known substrate of
these transporters is present within the cell at comparable
concentrations to glutamate. While OAT4 and OATP2B1
are not currently understood to transport glutamate, the
fact that the related transporters, OAT2 and OAT10, do
transport glutamate suggests that it is a possibility (Fork
et al. 2011; Schulz et al. 2014).
Here we report glutamate exchange on the BM of
human placental syncytiotrophoblast, which could not be
explained by known transporters. We provide evidence
that glutamate is a substrate for OAT4 and OATP2B1
and hence these transporters could mediate the observed
glutamate exchange. We therefore propose that organic
anionuptake fromthe feto-placental circulation is coupled
to glutamate cycling.
Methods
Term placentas from uncomplicated pregnancies were
collected with written informed consent from women
delivering at the Princess Anne Hospital in Southampton
with approval from the Southampton and Southwest
Hampshire Local EthicsCommittee (308/03/w).The study
conformed to the Declaration of Helsinki.
Placental perfusions
Placentas were perfused using the methodology of
Schneider (Schneider et al. 1972) as adapted in our
laboratory (Cleal et al. 2007, 2011). Placentas were
perfused with Earle’s bicarbonate buffer (EBB: 5mmol l−1
glucose, 1.8 mmol l−1 CaCl2, 0.4 mmol l−1 MgSO4,
116.4 mmol l−1 NaCl, 5.4 mmol l−1 KCl, 26.2 mmol l−1
NaHCO3, 0.9 mmol l−1 NaH2PO4) and gassed with 5%
CO2–95%O2 via the fetal catheter going into the chorionic
plate fetal artery at 6 ml min−1 and via five maternal
catheters at 14 ml min−1 using a roller pump.
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Initial perfusions were performed with 58 nmol l−1
[14C]glutamate and 1.4 μmol l−1 [3H]proline (Perkin
Elmer, MA, USA), which was perfused into the maternal
artery. Proline was included to determine whether
glutamate exchange could be mediated by the system
ASC. To stimulate exchange, 16 μmol boluses of
glutamate, glutamine, serine, salicylic acid, ibuprofen,
para-aminohippuric acid (PAH) and bromosulphothalein
(BSP) were perfused into the fetal circulation.
A second set of perfusions were performed with
58 nmol l−1 [14C]glutamate (Perkin Elmer) which was
perfused into the maternal artery. In these perfusions
the first fetal arterial bolus was 100 μmol aspartate, the
second 16 μmol BSP mixed with 100 μmol aspartate
(as an inhibitor of glutamate reuptake by EAAT trans-
porters, including SLC1A1, 2 and 3; Noorlander et al.
2004) and finally 16 μmol glutamate on its own. Boluses
were injected in a volume of 1.5 ml EBB over a 10–15 s
period.
When sampling, approximately 1.5 ml of venous
exudate was collected from maternal and fetal venous
outflows. Appearance of 14C-tracer into the medium was
measured by liquid scintillation counting (Packard-Perkin
Elmer, MA, USA). At the end of the experiments, the
perfused mass of placental cotyledon (which assumed
a white colour compared to non-perfused tissue) was
obtainedby trimmingoff the non-perfused tissue, blotting
and weighing.
Primary term human cytotrophoblast culture
Cytotrophoblast cells were isolated using an adaptation
of the method developed by Kliman et al. (1986) as
described previously (Greenwood et al. 1993). Isolated
cells were plated in culture medium (Dulbecco’s modified
Eagle’s medium andHam’s F-12 1:1, 10% heat inactivated
fetal calf serum, 0.6% glutamine and the antibiotics 1%
gentamicin, 0.2% penicillin and 0.2% streptomycin) onto
35mmculture dishes (Nunc), at a density of (2–2.5)× 106,
and were maintained in primary culture for 66 h at 37°C
in a humidified incubator (95% air–5% CO2).
rtPCR to determine exchanger gene expression
in placenta
Total RNA was extracted from term human placental
tissue or termhumanprimary cytotrophoblast culture and
reverse transcribed into cDNA. Primers were designed for
SLC7A13 (AGT-1), the OATs and the OATPs (Table 1).
rtPCR was carried out to determine expression under the
following conditions: 94°C for 3 min; 40 cycles at 94°C
for 30 s, 57–64°C (primer-specific annealing temperatures
are shown in Table 1) for 30 s and 72°C for 30 s; and
then 72°C for 4 min. Positive results were confirmed by
sequencing of the PCR product (GATC Biotech, Berlin,
Germany). Where no expression was detected in placenta,
primers were tested using cDNA from other cell lines or
tissues thought to express the gene of interest as outlined
in Table 1.
cRNA synthesis for microinjection into oocytes
Plasmids containing the cDNA of humanOAT4 or human
OATP2B1 obtained fromOriGene (OriGene Technologies
Inc., Rockville,MD,USA)were linearised using restriction
enzymes (Promega, Southampton, UK). Both plasmids
contained two T7 promoter sites and were double
digested before purification to prevent synthesis of cRNA
from the non-coding T7 site. The OAT4 plasmid was
digested with the restriction enzymes NdeI and StuI.
The OATP2B1 plasmid was digested with the restriction
enzymes NdeI and XhoI. cRNA was synthesised from
the coding T7 promoter using the Ambion mMachine
mMessage kit according to themanufacturer’s instructions
(Life Technologies, UK).
Xenopus oocyte trans-stimulation studies
Xenopus laevis oocytes were obtained from the European
Xenopus Resource Centre (Portsmouth, UK). Oocytes
were treated with collagenase (2 mg ml−1) in buffer OR2
(2.5mmol l−1 KCl, 82.5mmol l−1 NaCl, 1mmol l−1 CaCl2,
1 mmol l−1 Na2HPO4, 1 mmol l−1 MgCl2, 5 mmol l−1
Hepes) for 1 h at room temperature. Oocytes were then
incubated in ND91 buffer (2 mmol l−1 KCl, 91 mmol l−1
NaCl, 1.8 mmol l−1 CaCl2, 1 mmol l−1 MgCl2, 5 mmol l−1
Hepes, 1% penicillin/streptomycin and 0.1% gentamycin
sulphate) overnight at 18°C. Stage V oocytes were injected
with 20 ng of the cRNA for the transporter of interest
dissolved in 56 nl of water. The water-injected control
oocytes were injected with an equivalent volume of
water.
Two to three days after injection of the relevant trans-
porter cRNA, oocytes were preloadedwith [14C]glutamate
by incubating for 30 min in 20 μmol l−1 (50 μCi l−1)
[14C]glutamate in ND91 buffer and then washed 3 times
in 1 ml of ND91 buffer to remove extracellular label.
Initial time course experiments were performed to show
the [14C]glutamate efflux at 2, 5 and 8 min. For OAT4
time courses, oocytes were trans-stimulated by addition of
10 mmol l−1 glutamate to the extracellular ND91 buffer.
ForOATP2B1 time courses, oocytes were trans-stimulated
by addition of 20 mmol l−1 BSP to the extracellular
ND91 buffer. For OAT4, ND91 control experiments were
only performed at 5 min. Extracellular BSP was used to
trans-stimulate glutamate efflux in OATP2B1 expressing
oocytes as in preliminary experiments glutamate was not
shown to trans-stimulate significant glutamate efflux.
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Table 1. Primer and probe information
Gene Accession number Forward primer (5′–3′) Reverse primer (5′–3′) Annealing temp. (°C)
SLC7A13 (AGT-1) NM 138817.2 CTGTCCCAAAGCTGCCTAAG GAATTTCCCTGGGTGTCAGA 60
SLC22A6 (OAT1) NM 153277.2 GTCTGCAGAAGGAGCTGACC AGCAAGAGAGGTTCGGACAA 60
SLC22A7 (OAT2) NM 001184736.1 CCTCCAAGCTGCTGGTCTAC CATCCCTGTCTGTCTGAGCA 60
SLC22A8 (OAT3) NM 018484.2 GTCCATACGCTGGTTGGTCT GCTGTACCTCACCCGTGATT 60
SLC22A11 (OAT4) NM 018484.2 CAGAAAGGTGGCCAGGATAA CACCAGCATGTTGGCTAGAA 60
SLC22A10 (OAT5) NM 001039752.3 CACAGAACCCTGTGTGGATG TCGGAAGACATAAGCCAAGC 60
SLC22A9 (OAT7) NM 080866.2 AGGTTTGGGAGAAGGTTCGT TGCTGCCTCCAGTTCTTTTT 60
SLCO1A2 (OATP1A2) NM 001145211.2 GCTTGTCTTGCTGGTTGTGA GAATCCATTAAAGCGCCAAA 60
SLCO1B3 (OATP1B3) NM 019844.3 GTGGCTTGGTTTCCTTGTGT AGTTGCAACCGTAGGAATGG 60
SLCO2A1 (OATP2A1) NM 005630.2 ACGGTTTCCATGCATCTTTC ATGGCAAGGGGAGAGGTACT 60
SLCO2B1 (OATP2B1) NM 001145211.2 GGGAACACAGCCTTGATTGT CCATCATGGTCACTGCAAAC 60
SLCO3A1 (OATP3A1) NM 013272.3 TGCGGTGCCTTACTCTTCTT TAGCAAGCAGTGGACACCAG 60
SLCO4A1 (OATP4A1) NM 013272.3 CCCGTCTACATTGCCATCTT CTCAGGCTGAACTGGGACTC 61
SLCO4C1 (OATP4C1) NM 180991.4 GAGAAGCTCCGGTCACTGTC TGGGCACAGAATCATCAAGA 60
Based on time course experiments, further experiments
were performed at 5 min. For OAT4 the substrates added
to extracellular ND91 buffer to trans-stimulate effluxwere
10 mmol l−1 glycine, 10 mmol l−1 aspartate, 10 mmol l−1
para-aminohippuric acid (PAH), 10 mmol l−1 ibuprofen,
10 mmol l−1 glutamate, 10 and 20 mmol l−1 estrone
sulphate (E-3-S) and 10 and 20 mmol l−1 BSP. For
OATP2B1, the substrates added to extracellular ND91
buffer to trans-stimulate efflux were 10 and 20 mmol l−1
glycine, 10mmol l−1 glutamate, 10 and 20mmol l−1 E-3-S,
10 and 20 mmol l−1 BSP and 5 mmol l−1 pravastatin. For
each condition, efflux was determined in three batches of
10 oocytes injected with the cRNA of interest and three
batches of 10 control oocytes not expressing the trans-
porter of interest. Effluxof 14C-tracer into themediumwas
measured by liquid scintillation counting (Packard-Perkin
Elmer).
Each independent experiment used oocytes from a
different frog and experimentswere conducted in different
weeks.
Data analysis and statistics
For the perfusion experiments, trans-stimulation of
glutamate release was determined by calculating the area
under the curve (AUC) for the 15 min following injection
using the trapezium rule with the three points before the
bolus (t = −1, −2 and −3 min) and the points following
(t = 15, 17 and 21 min) defined as baseline. To determine
whether the AUC was greater than 0 (indicating efflux)
the data were analysed using Wilcoxon’s signed rank test.
For the oocyte experiments, total [14C]glutamate efflux
for each substrate over 5 min was compared to that of
ND91 buffer alone using Dunnett’s two-tailed multiple
comparison’s t test. Significance was assumed at P < 0.05
and data are presented as means ± SEM. For the time
course experiments, [14C]glutamate efflux for each sub-
strate and buffer alone was determined at 2, 5 and 8 min
and was compared to that of ND91, and a regression line
was plotted for efflux against time.Analysiswas performed
using IBM SPSS Statistics version 21.
Results
Glutamate stimulates release of [14C]glutamate into
the fetal circulation of the perfused placenta, while
other known OAT and OATP substrates do not
To identify the transportersmediating glutamate exchange
on the BMof the placental syncytiotrophoblast, substrates
of known amino acid exchangers were added to the fetal
circulation of the isolated perfused placenta to determine
if they would stimulate glutamate efflux.
Average perfused cotyledonweight was 45.5± 3.5 g and
average fetal venous recovery was 5.0 ± 0.2 ml min−1.
Over the course of the experiments, the base-
line percentage of the [14C]glutamate and [3H]proline
perfused into the maternal circulation reaching the fetal
circulation was 1.7 ± 0.3% for [14C]glutamate and
3.6 ± 0.6% for [3H]proline. Addition of a 16 μmol
glutamate bolus to the fetal circulation stimulated
significant release of [14C]glutamate (abovebaseline trans-
fer) into the fetal circulation (P = 0.002, n = 12,
Fig. 1A). No release of [14C]glutamate above baseline
was observed following 16 μmol fetal boluses of serine
(n = 5 placentas), glutamine (n = 5 placentas), salicylic
acid (n = 5 placentas), or BSP (n = 3 placentas, Fig. 1A).
Proline transfer was not altered following any of the fetal
boluses (data not shown).
In the second set of perfusions there was no release
of glutamate above baseline following an aspartate bolus
(n = 4, P = 0.76), but BSP + aspartate (n = 5, P = 0.04)
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stimulated release of [14C]glutamate from the placenta
(Fig. 1B).
Expression profile of OAT/OATP in term human
placenta and primary cytotrophoblast culture
To confirm reports in the literature that the known
glutamate exchangers AGT-1 and OAT2 were not
expressed in the placenta (Matsuo et al. 2002; Fork et al.
2011), rtPCR was performed on placental cDNA. rtPCR
was performed to confirm the presence of mRNA for
key members of the OAT and OATP transporter families
in placenta and cytotrophoblast culture. Expression of
SLC22A11 (OAT4), SLCO2A1 (OATP2A1), SLCO2B1
(OATP2B1) and SLCO4A1 (OATP4A1) were detected in
placenta and primary cytotrophoblast culture (Fig. 2),
and the result was confirmed by sequencing of the PCR
product. No expression of SLC22A6 (OAT1), SLC22A7
(OAT2), SLC22A8 (OAT3), SLC22A10 (OAT5), SLC22A9
(OAT7), SLCO1A2 (OATP1A2), SLCO1B3 (OATP1B3),
SLCO3A1 (OATP3A1), or SLCO4C1 (OATP4C1) was
detected in placenta or primary trophoblast cDNA
although the primers did amplify product in control
tissues (Fig. 2). No expression of the glutamate–aspartate
exchanger SLC7A13 (AGT-1) mRNA was detected in
human placenta by rtPCR (Fig. 2).
Glutamate efflux from oocytes expressing OAT4
or OATP2B1
In order to test the hypothesis that OAT4 and OATP2B1
transported glutamate, these proteins were expressed in
Xenopus oocytes and transport studies undertaken.
To account for endogenous glutamate release, release
of [14C]glutamate efflux was measured from oocytes
not expressing the protein of interest and this efflux
was subtracted from the release measured from oocytes
expressing the protein of interest. After preloading
by incubating with 20 μmol l−1 [14C]glutamate for
30 min, there was no significant difference in glutamate
uptake in the water-injected (17.3 ± 1.7 pmol/oocyte,
n = 7), non-injected (19.5 ± 2.0 pmol/oocyte, n = 10),
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Figure 1. Trans-stimulation of [14C]glutamate efflux into the fetal circulation of the isolated perfused
placenta following addition of boluses of potential exchanger substrates to the fetal circulation
A, trans-stimulation of [14C]glutamate efflux into the fetal circulationwas observed in exchange for fetal glutamate,
but none of the other potential exchange substrates. Data presented represent the increase in glutamate transfer
as the area under the curve (AUC) above baseline release. ∗P = 0.002 vs. baseline, n = 3–12. B, aspartate bolus
alone did not stimulate glutamate efflux but aspartate in combination with the OAT4 and OATP2B1 substrate BSP
(used in combination to inhibit glutamate reuptake by EAAT transporters) stimulated observable exchange. n = 5,
∗P = 0.04 vs. baseline.
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OAT4-injected (20.6 ± 2.6 pmol/oocyte, n = 10) or
OATP2B1-injected (17.3 ± 1.6 pmol/oocyte, n = 5)
oocytes. Assuming an intra-oocyte volume of 0.4 μl
(Taylor & Smith, 1987), this is the equivalent of
48 μmol l−1 [14C]glutamate in a total intracellular
glutamate concentration of 4 mmol l−1, indicating that
there will be significant tracer dilution within the oocyte.
When trans-stimulated with 10 mmol l−1 glutamate,
efflux of [14C]glutamate from OAT4-injected oocytes
increased in a linear manner with time (R = 0.73,
n = 3, Fig. 3). Similarly, efflux of [14C]glutamate from
OATP2B1-injected oocytes increased in a linear manner
with time when trans-stimulated with 20 mmol l−1 BSP
(R = 0.67, n = 3, Fig. 3).
Trans-stimulation of glutamate efflux from Xenopus
oocytes expressing OAT4
The function of OAT4 when expressed in oocytes was
tested by measuring the ability of known OAT4 sub-
strates to trans-stimulate [14C]glutamate efflux. In oocytes
expressing OAT4, there was significant OAT4 mediated
effluxof [14C]glutamate following a 5min incubationwith
10 mmol l−1 glutamate (n = 10), 10 mmol l−1 (n = 5) or
20 mmol l−1 (n = 5) estrone sulphate or 20 mmol l−1
BSP (n = 5) (P < 0.05, Fig. 4) when compared to control
oocytes. Importantly, there was no significant efflux of
[14C]glutamate from OAT4 expressing oocytes following
a 5 min incubation with ND91 buffer alone (n = 10) or
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Figure 2. Expression of OATs and OATPs in term human placenta and primary cytotrophoblast
A, rtPCR amplification of cDNA from term human placenta, control tissue (kidney or liver) and no template control
(NTC) for the OATs. B, rtPCR amplification of cDNA from term human placenta, control tissue (kidney, brain or
liver) and NTC for OATP1A2, OATP1B3, OATP3A1, OATP4C1. C, rtPCR amplification of cDNA from term human
placenta and NTC for OATP2A1, OATP4A1 and OATP2B1. D, rtPCR amplification of cDNA from term human
placenta, control tissue (kidney) and NTC for AGT-1. E, rtPCR amplification of cDNA from primary term human
cytotrophoblast culture and in NTC for OATP2B1, OATP2B1, OATP4A1 and OAT4. plac, placenta; kid, kidney; liv,
liver; cyto, cytotrophoblast.
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with 10 mmol l−1 glycine (n = 8), 10 mmol l−1 BSP, or
10 mmol l−1 aspartate (n = 5) (Fig. 4).
Trans-stimulation of glutamate efflux from Xenopus
oocytes expressing OATP2B1
The function of OATP2B1 when expressed in oocytes
was tested by measuring the ability of known OATP2B1
substrates to trans-stimulate [14C]glutamate efflux. In
oocytes expressing OATP2B1, when compared to control
oocytes, there was significant OATP2B1 mediated efflux
of [14C]glutamate following a 5 min incubation with
20 mmol l−1 estrone-3-sulphate (n = 5), 20 mmol l−1
BSP (n= 5) and 5mmol l−1 pravastatin (n= 3) (P< 0.05,
Fig. 5). There was no significant efflux of [14C]glutamate
from OATP2B1 expressing oocytes following a 5 min
incubation with ND91 buffer alone (n = 5), 10 or
20 mmol l−1 glycine (n = 5), 10 mmol l−1 glutamate
(n= 5), 10mmol l−1 estrone sulphate or 10mmol l−1 BSP
(Fig. 5). OATP2B1 therefore appears tomediate glutamate
efflux but not glutamate uptake.
Discussion
This study demonstrates for the first time that OAT4
and OATP2B1 mediate glutamate efflux and that, in the
placenta, uptake of the OAT4 andOATP2B1 substrate BSP
is coupled to release of glutamate. That glutamate can act
as a counter-ion for these transporters is physiologically
important, as its high intracellular concentration will
provide a chemical gradient to drive placental uptake of
OAT4 and OATP2B1 substrates from the fetal circulation.
Furthermore, rapid reuptake of glutamate released by
OAT4 and OATP2B1 will maintain this gradient. These
findings suggest that organic anion transport is coupled
to cycling of glutamate across the BM of placental
syncytiotrophoblast.
The initial perfusion data demonstrate exchange of
glutamate for glutamate but not for other substrates of any
candidate transporters including OAT4 and OATP2B1. To
explain these observations we proposed that there was
glutamate efflux by exchange, but that the [14C]glutamate
released from the placenta did not appear in the fetal vein
due to rapid reuptake by the high affinity EAAT trans-
porters on the BM (Day et al. 2013). In the one case where
[14C]glutamate efflux was observed, in exchange for a fetal
glutamate bolus, this can be explained by the fact that the
fetal glutamate bolus will both stimulate [14C]glutamate
efflux and competitively inhibit its reuptake by the EAAT
transporters. Consistent with our new proposal, while
there was no exchange for aspartate alone, in the presence
of aspartate thehigh affinityOAT4andOATP2B1 substrate
BSP did stimulate observable release of [14C]glutamate.
Consistent with previous studies we show expression
OAT4, OATP2B1, OATP2A1 and OATP4A1 in the human
placenta (St-Pierre et al. 2002; Ugele et al. 2003). However,
no other OAT or OATP transporters were shown to be
expressed. In addition, we confirm that the glutamate
exchanger SLC7A13 (AGT-1) is not expressed in human
placenta and so cannot be mediating the observed
glutamate exchange (Matsuo et al. 2002).
Glutamate uptake by the syncytiotrophoblast BM is
known to be mediated by highly accumulative EAAT
transporters (Day et al. 2013). The fact that efflux of
[14C]glutamate could only be observed in the presence
of glutamate or aspartate, which would competitively
inhibit these transporters, suggests that they also mediate
rapid uptake of glutamate released by OAT4 and or
OATP2B1. Glutamate cycling on the BM of the placental
syncytiotrophoblast would energetically couple organic
anion transport to the Na+ gradient maintained by the
0 2 4 6 8 10
0
10
20
30
40
Time (minutes)
(p
m
ol
/1
0 
oo
cy
te
s/
5 
m
in
)
14
C
-g
lu
ta
m
te
 e
ffl
ux
OATP2B1 BSP 20 mM
OAT4 glutamate 10 mM
OATP2B1 buffer only
OAT4 buffer only
Figure 3. Trans-stimulation of glutamate efflux by
extracellular exchange substrates increases in a linear
manner between 2 and 8 min
In Xenopus oocytes expressing OAT4 or OATP2B1 the addition of
extracellular exchange substrate (glutamate for OAT4 and BSP for
OATP2B1) led to a time-dependent increase in [14C]glutamate
efflux. In contrast, there was no efflux in the absence of
extracellular exchange substrate. Data are means and SEM,
n = 3.
C© 2015 The Authors The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
4556 E. M. Lofthouse and others J Physiol 593.20
Na+/K+-ATPase. Recycling glutamate will maintain the
intracellular glutamate gradient and thus the driving force
for organic anion uptake. EAAT transporters are widely
expressed and glutamate cycling could potentially drive
influxofOAT4andOATP2B1 substrates inother cell types.
Glutamate concentrations in fetal plasma are around
36 μmol l−1 (Cetin et al. 2005) suggesting that there
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oocytes expressing OAT4
Efflux of intracellular [14C]glutamate was trans-stimulated by the
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and bromosulphothalein (BSP). ∗P < 0.05 vs. ND91, n = 5
independent experiments. Data represent total efflux of
[14C]glutamate into buffer in 5 min.
may be futile cycling of glutamate via OAT4. Exchangers
which use the gradients of higher abundance substrates
to accumulate lower abundance substrates will inevitably
undertake futile cycling to some degree. While it may
appear inefficient, futile cycling does not alter the trans-
membrane gradient and is energetically neutral so it does
not matter to the cell as long as the lower abundance
(but probably higher affinity) substrates are accumulated
within the cell. However, as the EAAT transporters in
the BM have a high affinity for glutamate (Kanai et al.
2013), it is likely that glutamate concentrations at the basal
membrane are lower than in the fetal vein and futile cycling
is minimised.
Both OAT4 and OATP2B1 are expressed in the placenta
andhavebeen localised to theBM(Ugele et al.2003).While
neither of these transporters had previously been shown
to transport glutamate, the observation of [14C]glutamate
efflux in exchange for their substrate BSP suggested
that this was a possibility. When expressed in Xenopus
oocytes, both OAT4 and OATP2B1 were indeed found
to mediate glutamate efflux. OAT4 was also found to
mediate glutamate uptake and so is most likely to be
responsible for the observed glutamate for glutamate
exchange. In the placenta, coupling BM organic anion
transport to the glutamate gradientwouldprovide a strong
driving force for the removal of xenobiotics and uptake
of steroid sulphates from the fetal circulation (Fig. 6).
This is because high glutamate levels will competitively
inhibit efflux of other substrates and increase the rate at
which the binding site is recycled to the extracellular face
of the membrane. Both inhibiting efflux and increased
opportunity for uptake will increase the accumulation
of extracellular substrates within the cell. OAT4 and
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OATP2B1 are also expressed in other tissues, such as
kidney and liver, where the glutamate gradient would
enhance their ability to drive intracellular accumulation
of biological or pharmacological substrates (e.g. statins)
(Hagenbuch & Stieger, 2013; Koepsell, 2013).
Previous studies have suggested that α-ketoglutarate
and orotic acid may provide the countervailing gradients
for specific OATs (Pritchard, 1995; Fork et al. 2011), yet
the transmembrane gradient of these substrates is low
compared to that of glutamate, limiting their potential to
drive accumulation of extracellular substrates (Panitchob
et al. 2015). However, the relative affinities of the
potential exchange substrates, such as α-ketoglutarate,
may also need to be considered. That transport by
OATP2B1 is coupled to a significant substrate gradient
is consistent with the observation that the anti-diabetic
drug glibenclamide, a substrate of OATP2B1, has an intra-
cellular concentration 50 times that in plasma, something
which would require an active transport mechanism
(Hagenbuch & Stieger, 2013; Day et al. 2013).
There are several experimental considerations which
need to be taken into account when interpreting these
data. First, that [14C]glutamate taken up into the
placenta or oocyte will become diluted in a much
larger pool of endogenous glutamate. This means that
when measuring efflux we will only measure a small
proportion of the glutamate coming out (proportional
to the dilution of [14C]glutamate in the intracellular
pool). This could explain why relatively high levels of
exchange substrate were required to see maximal efflux.
Secondly we cannot exclude conversion of [14C]glutamate
to α-[14C]ketoglutarate. As α-ketoglutarate, and other
anionic metabolites of glutamate, are potentially
substrates of these transporters, we cannot exclude
that we are measuring efflux of these rather than
glutamate. However, given the dilution of tracer within
the cell, production of α-ketoglutarate will primarily
occur from unlabelled glutamate and as such, any
α-[14C]ketoglutaratewouldbehighlydilute. Furthermore,
aspartate would not be expected to block reuptake of
α-[14C]ketoglutarate. These issues could be addressed in
future experiments using liquid chromatography–mass
spectrometry (LCMS) based approaches.
Glutamate was able to trans-stimulate efflux of intra-
cellular [14C]glutamate via OAT4, but we did not see
clear evidence for trans-stimulation of glutamate efflux via
OATP2B1. This provides indirect evidence that glutamate
is taken up by OAT4 but as we did not observe uptake
directly we cannot exclude the possibility that gluta-
mate was acting as a trans-activator, as has been observed
to occur for benzoic acid and OAT2 (Pfennig et al. 2013).
Direct uptake studies are also required to determine
whether or not OATP2B1 mediates glutamate uptake.
Differential intra- and extracellular substrate affinity has
previously been observed for other exchangers including
the recent observation that OAT10 mediates glutamate
efflux but not influx (Meier et al. 2002; Schulz et al. 2014).
OATP transporters, includingOATP2B1, have been shown
to have higher and lower affinity binding sites and this
needs to be taken into account in future kinetic analysis
of glutamate uptake and efflux by OATP2B1 and OAT4
(Shirasaka et al. 2012; Liu et al. 2013).
While the focus of this work was on the placenta, the
findings are potentially relevant to all cells expressing
these transporters. In the case of OATP2B1, the
glutamate gradientwould increase its ability to accumulate
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Figure 6. The glutamate gradient may
drive uptake of OAT4 and OATP2B1
substrates from the fetus
Once in the placenta these can be transported
to the mother in the case of xenobiotics or, in
the case of DHEAS, used for placental
synthesis of oestrogen. Glutamate reuptake is
mediated by high affinity EAAT glutamate
transporters which maintain the glutamate
gradient. Glutamate efflux in exchange for
OAT substrates could only be observed in the
perfused placenta if reuptake via EAAT was
blocked with aspartate. This suggests recycling
of glutamate back to the syncytiotrophoblast.
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its substrates, e.g. statins, within hepatocytes where
they can inhibit 3-hydroxy-3-methylglutaryl-coenzyme A
(HMG-CoA) and in muscle where they are linked to
statin-induced myopathy (Hagenbuch & Stieger, 2013).
OAT4 is expressed on the apical membrane of the renal
proximal tubular epithelium where it has been hypo-
thesised tomediate reuptake of organic anions in exchange
for an unidentified intracellular anion which we suggest is
likely to be glutamate (Ekaratanawong et al. 2004).
The observation that glutamate efflux occurs by OAT2,
OAT4, OAT10 andOATP2B1 raises the possibility that it is
a more widespread feature of the OAT and OATP families
than had previously been appreciated (Fork et al. 2011;
Schulz et al. 2014). This family characteristic may have
eluded detection as most studies measure uptake, but if,
as for OATP2B1, glutamate efflux was the predominant
mode of action, studies focusing on uptake may not have
observed glutamate transport.
Understanding the gradients that determine the activity
of these exchange transporters will also be important
for pharmacokinetic modelling of drug transport in the
placenta and other tissues (Lewis et al. 2013; Staud &
Ceckova, 2015). Modelling also provides a framework
within which to test our assumptions about the nature
of transporter activity (Panitchob et al. 2015; Widdows
et al. 2015).
This study demonstrates that OAT4 and OATP2B1
mediate glutamate efflux and that the uptake of organic
anions across the BM of placental syncytiotrophoblast
may be coupled to cycling of glutamate. Coupling organic
anion transport to glutamate cyclingwouldmean that they
are able to accumulate substrates within the cell much
more effectively than if exchanging for a counter-ion with
a lower transmembrane gradient. These findings have
implications for our understanding of the biology and
pharmacokinetics ofOAT4 andOATP2B1 (Watanabe et al.
2011). Further studies in other members of the OAT and
OATP families are warranted to determine if glutamate
cycling is a driver of their activity.
References
Barle H, Ahlman B, Nyberg B, Andersson K, Essen P &
Wernerman J (1996). The concentrations of free amino acids
in human liver tissue obtained during laparoscopic surgery.
Clin Physiol 16, 217–227.
Cetin I, de Santis MS, Taricco E, Radaelli T, Teng C, Ronzoni S,
Spada E, Milani S & Pardi G (2005). Maternal and fetal
amino acid concentrations in normal pregnancies and in
pregnancies with gestational diabetes mellitus. Am J Obstet
Gynecol 192, 610–617.
Cleal JK, Brownbill P, Godfrey KM, Jackson JM, Jackson AA,
Sibley CP, Hanson MA & Lewis RM (2007). Modification of
fetal plasma amino acid composition by placental amino
acid exchangers in vitro. J Physiol 582, 871–882.
Cleal JK, Glazier JD, Ntani G, Crozier SR, Day PE, Harvey NC,
Robinson SM, Cooper C, Godfrey KM, Hanson MA & Lewis
RM (2011). Facilitated transporters mediate net efflux
of amino acids to the fetus across the basal membrane
of the placental syncytiotrophoblast. J Physiol 589,
987–997.
Day PEL, Cleal JK, Lofthouse EM, Goss V, Koster G, Postle A,
Jackson JM, Hanson MA, Jackson AA & Lewis RM (2013).
Partitioning of glutamine synthesised by the isolated
perfused human placenta between the maternal and fetal
circulations. Placenta 34, 1223–1231.
Ekaratanawong S, Anzai N, Jutabha P, Miyazaki H, Noshiro R,
Takeda M, Kanai Y, Sophasan S & Endou H (2004). Human
organic anion transporter 4 is a renal apical organic
anion/dicarboxylate exchanger in the proximal tubules. J
Pharmacol Sci 94, 297–304.
Fork C, Bauer T, Golz S, Geerts A, Weiland J, Del Turco D,
Schomig E & Grundemann D (2011). OAT2 catalyses efflux
of glutamate and uptake of orotic acid. Biochem J 436,
305–312.
Greenwood S, Brown P, Edwards D & Sibley C (1993). Patch
clamp studies of human placental cytotrophoblast cells in
culture. Trophoblast Res 7, 53–68.
Hagenbuch B & Stieger B (2013). The SLCO (former SLC21)
superfamily of transporters.Mol Aspects Med 34, 396–412.
Kanai Y, Clemencon B, Simonin A, Leuenberger M, Lochner
M, Weisstanner M & Hediger MA (2013). The SLC1
high-affinity glutamate and neutral amino acid transporter
family.Mol Aspects Med 34, 108–120.
Kliman HJ, Nestler JE, Sermasi E, Sanger JM & Strauss JF 3rd
(1986). Purification, characterization, and in vitro
differentiation of cytotrophoblasts from human term
placentae. Endocrinology 118, 1567–1582.
Koepsell H (2013). The SLC22 family with transporters of
organic cations, anions and zwitterions.Mol Aspects Med 34,
413–435.
Lewis RM, Brooks S, Crocker IP, Glazier J, Hanson MA,
Johnstone ED, Panitchob N, Please CP, Sibley CP, Widdows
KL & Sengers BG (2013). Review: Modelling placental
amino acid transfer – From transporters to placental
function. Placenta 34, S46–S51.
Liu X, Huang J, Sun Y, Zhan K, Zhang Z & Hong M (2013).
Identification of multiple binding sites for substrate
transport in bovine organic anion transporting polypeptide
1a2. Drug Metab Dispos 41, 602–607.
Matsuo H, Kanai Y, Kim JY, Chairoungdua A, Kim DK,
Inatomi J, Shigeta Y, Ishimine H, Chaekuntode S, Tachampa
K, Choi HW, Babu E, Fukuda J & Endou H (2002).
Identification of a novel Na+-independent acidic amino acid
transporter with structural similarity to the member of a
heterodimeric amino acid transporter family associated
with unknown heavy chains. J Biol Chem 277,
21017–21026.
Meier C, Ristic Z, Klauser S & Verrey F (2002). Activation of
system L heterodimeric amino acid exchangers by
intracellular substrates. EMBO J 21, 580–589.
Noorlander CW, de Graan PN, Nikkels PG, Schrama LH &
Visser GH (2004). Distribution of glutamate transporters in
the human placenta. Placenta 25, 489–495.
C© 2015 The Authors The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
J Physiol 593.20 Coupling of glutamate and organic anion transport in placenta 4559
Panitchob N, Widdows KL, Crocker IP, Hanson MA, Johnstone
ED, Please CP, Sibley CP, Glazier JD, Lewis RM & Sengers
BG (2015). Computational modelling of amino acid
exchange and facilitated transport in placental membrane
vesicles. J Theor Biol 365, 352–364.
Pfennig T, Herrmann B, Bauer T, Schomig E & Grundemann D
(2013). Benzoic acid and specific 2-oxo acids activate hepatic
efflux of glutamate at OAT2. Biochim Biophys Acta 1828,
491–498.
Philipps AF, Holzman IR, Teng C & Battaglia FC (1978). Tissue
concentrations of free amino acids in term human placentas.
Am J Obstet Gynecol 131, 881–887.
Pritchard JB (1995). Intracellular α-ketoglutarate controls the
efficacy of renal organic anion transport. J Pharmacol Exp
Ther 274, 1278–1284.
Prouillac C & Lecoeur S (2010). The role of the placenta in fetal
exposure to xenobiotics: importance of membrane
transporters and human models for transfer studies. Drug
Metab Dispos 38, 1623–1635.
Sato H, Tamba M, Ishii T & Bannai S (1999). Cloning and
expression of a plasma membrane cystine/glutamate
exchange transporter composed of two distinct proteins.
J Biol Chem 274, 11455–11458.
Schneider H, Panigel M & Dancis J (1972). Transfer across the
perfused human placenta of antipyrine, sodium and leucine.
Am J Obstet Gynecol 114, 822–828.
Schulz C, Fork C, Bauer T, Golz S, Geerts A, Schomig E &
Grundemann D (2014). SLC22A13 catalyses unidirectional
efflux of aspartate and glutamate at the basolateral
membrane of type A intercalated cells in the renal collecting
duct. Biochem J 457, 243–251.
Shirasaka Y, Mori T, Shichiri M, Nakanishi T & Tamai I (2012).
Functional pleiotropy of organic anion transporting
polypeptide OATP2B1 due to multiple binding sites. Drug
Metab Pharmacokinet 27, 360–364.
Siiteri PK (2005). The continuing saga of
dehydroepiandrosterone (DHEA). J Clin Endocrinol Metab
90, 3795–3796.
St-Pierre MV, Hagenbuch B, Ugele B, Meier PJ & Stallmach T
(2002). Characterization of an organic anion-transporting
polypeptide (OATP-B) in human placenta. J Clin Endocrinol
Metab 87, 1856–1863.
Stanley CA (2009). Regulation of glutamate metabolism and
insulin secretion by glutamate dehydrogenase in
hypoglycemic children. Am J Clin Nutr 90, 862S–866S.
Staud F & Ceckova M (2015). Regulation of drug transporter
expression and function in the placenta. Expert Opin Drug
Metab Toxicol 11, 533–555.
Taylor MA & Smith LD (1987). Accumulation of free amino
acids in growing Xenopus laevis oocytes. Dev Biol 124,
287–290.
Ugele B, St-Pierre MV, Pihusch M, Bahn A & Hantschmann P
(2003). Characterization and identification of steroid sulfate
transporters of human placenta. Am J Physiol Endocrinol
Metab 284, E390–398.
Vinnars E, Furst P, Liljedahl SO, Larsson J & Schildt B (1980).
Effect of parenteral nutrition on intracellular free amino
acid concentration. JPEN J Parenter Enteral Nutr 4,
184–187.
Watanabe T, Kusuhara H, Watanabe T, Debori Y, Maeda K,
Kondo T, Nakayama H, Horita S, Ogilvie BW, Parkinson A,
Hu Z & Sugiyama Y (2011). Prediction of the overall renal
tubular secretion and hepatic clearance of anionic drugs and
a renal drug-drug interaction involving organic anion
transporter 3 in humans by in vitro uptake experiments.
Drug Metab Dispos 39, 1031–1038.
Widdows KL, Panitchob N, Crocker IP, Please CP, Hanson
MA, Sibley CP, Johnstone ED, Sengers BG, Lewis RM &
Glazier JD (2015). Integration of computational modeling
with membrane transport studies reveals new insights into
amino acid exchange transport mechanisms. FASEB J 29,
2583–2594.
Additional information
Competing interests
The authors have no competing interests to declare.
Author contributions
R.L., E.L., S.B., K.P., M.H. and I.O. were involved in conception
and design of experiments. E.L. undertook all experimental
analysis. E.L., R.L., K.P. and I.O. were involved in data analysis.
All authors contributed to the writing of the paper and approved
the final version for publication.
Funding
This workwas funded by theGerald Kerkut Charitable Trust and
the BBSRC (BB/L020823/1, BB/I011315/1). M.A.H. was funded
by the British Heart Foundation (CH-02-01).
Acknowledgements
We would like to thank midwives at the Princess Anne Hospital
for their assistance and Dr Susan Greenwood for advice and
assistance in establishing cytotrophoblast cell isolation and
culture.
C© 2015 The Authors The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
